RGNXREGENXBIO Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−29% vs 200-day) and heavily shorted (+15% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −29% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RGNX is trading
REGENXBIO Inc. is −45% over the past year while the S&P 500 is +16%: 61 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −29%
vs 200-day average · a clear downtrend
- RSI (14)
- 36
RSI (14) · neutral
- Below its 52-week high
- 58%
Below its 52-week high
Details›
- Last close2026-10-23
- $6.68
- 1 monthS&P 500 −0.94%
- −7.7%
- 1 yearS&P 500 +16%
- −45%
- 5 yearsS&P 500 +86%
- −81%
- vs 50-day average$8.40
- −21%
- 52-week high
- $15.98
- 52-week low
- $5.65
- Annualised volatility
- 89%
| Year | Return |
|---|---|
| 2026 (year to date) | −54% |
| 2025 | +86% |
| 2024 | −57% |
| 2023 | −21% |
| 2022 | −31% |
| 2021 | −28% |
| 2020 | +11% |
| 2019 | −2.3% |
| 2018 | +26% |
| 2017 | +79% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | −8.4% |
| Feb | 10 | 3 of 10 | +1.3% |
| Mar | 10 | 6 of 10 | +1.9% |
| Apr | 10 | 7 of 10 | +4.6% |
| May | 10 | 2 of 10 | −6.3% |
| Jun | 10 | 7 of 10 | +15% |
| Jul | 11 | 4 of 11 | −1.9% |
| Aug | 11 | 4 of 11 | +1.4% |
| Sep | 11 | 6 of 11 | +4.6% |
| Oct | 11 | 4 of 11 | −4.4% |
| Nov | 10 | 7 of 10 | +13% |
| Dec | 10 | 4 of 10 | −2.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.